$CRDF Cashflow Statement | Understand Stock

$CRDF

$0.88 +$0.07 (8.8%) Close

$CRDF Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of assets
Impairment loss
Depreciation
Stock-based compensation expense
Amortization of right-of-use assets
Accretion of discounts on short-term investments, net
Change in fair value of derivative financial instruments—warrants
Release of clinical trial funding commitment
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivable
Prepaid expenses and other current assets
Operating lease right-of-use assets
Other assets
Accounts payable and accrued liabilities
Operating lease liabilities
Other liabilities

Net cash used in operating activities
Investing activities:
Capital expenditures
Insurance proceeds from casualty loss
Maturities of short-term investments
Purchases of short-term investments
Sales of short-term investments
Net cash provided by investing activities
Financing activities:
Proceeds from sales of common stock, net of expenses of $0 and $3,286, respectively
Costs related to the clinical trial funding commitment
Proceeds from exercise of warrants, net of expense of $169 and $0, respectively
Proceeds from exercise of options
Borrowings under note payable
Repayments of note payable
Net cash provided by financing activities

Net change in cash and cash equivalents
Cash and cash equivalents - Beginning of year
Cash and cash equivalents - End of year
Cash paid for taxes
Supplemental disclosure of non-cash investing activities:
Accretion of Series A Convertible Preferred Stock dividend
Common stock, Series D Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $0 and $488, respectively
Cumulative preferred stock dividend adjustment
Cash paid for taxes
Purchases of unsettled short-term investments included in accrued liabilities

Comments